Wiebe, SamuelJetté, NathalieKorngut, Lawrence2013-11-192014-03-152013-11-192013Korngut, L. (2013). Intranasal Insulin for Treatment of Diabetic Polyneuropathy (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/26624http://hdl.handle.net/11023/1163Intranasal insulin administration is a novel approach to slow the progression of diabetic polyneuropathy (DPN). We performed a pilot randomized controlled trial of intranasal insulin in 12 type 1 diabetes mellitus patients with DPN to assess safety. We administered intranasal insulin for 6 weeks using biweekly dose-escalation up to 160 IU/d or intranasal saline. The primary outcome measure was frequency of hypoglycaemia. Frequency of mild (mHG) and serious hypoglycaemic (sHG) events was recorded. Secondary outcomes included clinical (Utah Early Neuropathy Score (UENS)) and laboratory (corneal confocal microscopy and electrophysiology) measures. There were no differences in glycemia between groups after supervised initial administration. The 40 IU/d and 80 IU/d doses were safe and well tolerated with comparable mHG events between groups. One intranasal insulin subject suffered a sHG at home while receiving 160 IU/d. Intranasal insulin was safe and well tolerated at 40 and 80 IU/d.engUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.NeuroscienceMedicine and SurgeryPharmacologyDiabetesInsulintreatmentNeuropathymaster thesis10.11575/PRISM/26624